entertainment -WSS

entertainment

author：comprehensive 2025-10-02 20:52:58 - browse：9782

Mathai Mammen crosses his arms and looks into the camera — coverage from STAT — FogPharma CEO Mathai Mammen Boston Globe Photo Import

Oncology startup FogPharma just closed a $145 million Series E round, the company confirmed, reaching a late stage of financing that few other biotechs have hit in recent years.

FogPharma, which is headquartered in Cambridge, Mass., is developing cancer treatments using corkscrew-shaped peptides called helicons that could possibly better breach cells.

As CEO Mathai Mammen sees it, very few exemplary medicines shuttle off of drug companies’ pipelines, wade through clinical trials, and end up in the hands of physicians and patients in a given year. Far more often, pharma and biotech companies are pushing out drugs that are incrementally better than what came before, extending cancer patients’ survival by a few more months, halting their tumor growth for a little while longer. But FogPharma could deliver something truly unique, Mammen said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： NIH fellows want a pay raise. Will that mean less money for grants?

Wikipedia

hotspot

WSS

NIH fellows want a pay raise. Will that mean less money for grants?

Sutter Health’s antitrust win overturned by appeals court

An outdated Medicare rule harms dementia patients with anxiety

Oak trusses raised to roof of fire

How CO2 helps viruses stay alive longer in the air

Eli Lilly’s Zepbound improved liver scarring in mid

knowledge

entertainment

hotspot

In age of alternative facts, a scholarly course on calling out crap

HCA discloses massive data breach affecting 11 million patients

Alkermes shareholders re

Structure Therapeutics oral GLP

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

UnitedHealth CEO's Medicaid comments send insurer stocks diving

23andMe had bad news about my health. I wish a person had delivered it

Leqembi, other new Alzheimer’s drugs require better biomarkers

Virginia high school admissions case could be legal follow

Sutter Health’s antitrust win overturned by appeals court

Wikipedia

Elizabeth Holmes on track for early release from her 11

Leqembi, other new Alzheimer’s drugs require better biomarkers

Structure Therapeutics oral GLP

BD to buy Edwards patient monitoring unit for $4.2 billion

Illumina board agrees to spin off Grail, as divestment plans proceed

Structure Therapeutics oral GLP

entertainment

Wikipedia

hotspot

focus